In vitro inhibition of HIV-1 proteinase by cerulenin
- PMID: 1690152
- DOI: 10.1016/0014-5793(90)80595-a
In vitro inhibition of HIV-1 proteinase by cerulenin
Abstract
Retroviruses encode proteinases necessary for the proteolytic processing of the viral gag and gag-pol precursor proteins. These enzymes have been shown to be structurally and functionally related to aspartyl proteinases such as pepsin and renin. Cerulenin is a naturally occurring antibiotic, commonly used as an inhibitor of fatty acid synthesis. Cerulenin has been observed to inhibit production of Rous sarcoma virus and murine leukaemia virus by infected cells, possibly by interfering with proteolytic processing of viral precursor proteins. We show here that cerulenin inhibits the action of the HIV-1 proteinase in vitro, using 3 substrates: a synthetic heptapeptide (SQNYPIV) which corresponds to the sequence at the HIV-1 gag p17/p24 junction, a bacterially expressed gag precursor, and purified 66 kDa reverse transcriptase. Inhibition of cleavage by HIV-1 proteinase required preincubation with cerulenin. Cerulenin also inactivates endothiapepsin, a well-characterised fungal aspartyl proteinase, suggesting that the action of cerulenin is a function of the common active site structure of the retroviral and aspartic proteinases. Molecular modelling suggests that cerulenin possesses several of the necessary structural features of an inhibitor of aspartyl proteinases and retroviral proteinases. Although cerulenin itself is cytotoxic and inappropriate for clinical use, it may provide leads for the rational design of inhibitors of the HIV proteinase which could have application in the chemotherapy of AIDS.
Similar articles
-
Rational design of peptide-based HIV proteinase inhibitors.Science. 1990 Apr 20;248(4953):358-61. doi: 10.1126/science.2183354. Science. 1990. PMID: 2183354
-
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues.Nature. 1990 Jan 4;343(6253):90-2. doi: 10.1038/343090a0. Nature. 1990. PMID: 1688646
-
Substitutions at the P2' site of gag p17-p24 affect cleavage efficiency by HIV-1 protease.Biochem Biophys Res Commun. 1990 Mar 16;167(2):554-60. doi: 10.1016/0006-291x(90)92060-d. Biochem Biophys Res Commun. 1990. PMID: 2182016
-
Subsite preferences of retroviral proteinases.Methods Enzymol. 1994;241:254-78. doi: 10.1016/0076-6879(94)41068-2. Methods Enzymol. 1994. PMID: 7854181 Review. No abstract available.
-
Specificity of retroviral proteases: an analysis of viral and nonviral protein substrates.Methods Enzymol. 1994;241:279-301. doi: 10.1016/0076-6879(94)41069-0. Methods Enzymol. 1994. PMID: 7854182 Review. No abstract available.
Cited by
-
Targeting Cancer Metabolism and Current Anti-Cancer Drugs.Adv Exp Med Biol. 2021;1286:15-48. doi: 10.1007/978-3-030-55035-6_2. Adv Exp Med Biol. 2021. PMID: 33725343 Review.
-
Cleavage of the HIV-1 p66 reverse transcriptase/RNase H by the p9 protease in vitro generates active p15 RNase H.Arch Virol. 1991;118(3-4):179-88. doi: 10.1007/BF01314028. Arch Virol. 1991. PMID: 1712581
-
Structure-based design of nonpeptide inhibitors specific for the human immunodeficiency virus 1 protease.Proc Natl Acad Sci U S A. 1990 Sep;87(17):6644-8. doi: 10.1073/pnas.87.17.6644. Proc Natl Acad Sci U S A. 1990. PMID: 2204060 Free PMC article.
-
Fatty acid synthesis: a potential selective target for antineoplastic therapy.Proc Natl Acad Sci U S A. 1994 Jul 5;91(14):6379-83. doi: 10.1073/pnas.91.14.6379. Proc Natl Acad Sci U S A. 1994. PMID: 8022791 Free PMC article.
-
EHFPI: a database and analysis resource of essential host factors for pathogenic infection.Nucleic Acids Res. 2015 Jan;43(Database issue):D946-55. doi: 10.1093/nar/gku1086. Epub 2014 Nov 20. Nucleic Acids Res. 2015. PMID: 25414353 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources